Clinical Trials Logo

Clinical Trial Summary

The study investigates response assessment of gastrointestinal stromal tumors using Dual Energy CT (DECT) in patients undergoing targeted therapy with a TKI Inhibitor.


Clinical Trial Description

Patients treated with targeted therapies by tyrosine kinase inhibition (TKI) almost always show different response patterns than tumors treated with cytotoxic chemotherapy. Tumor manifestations treated with targeted therapies often show only minor measurable changes in tumor size despite inhibition of tumor proliferation. Decrease in tumor size fulfilling the criteria of a partial remission according to RECIST may occur at a delayed stage of treatment after several months (PMID 19620483). Sometimes, even an initial increase of maximum tumor diameters may be observed although those patients are treatment responders with respect to 'hard' study endpoints like overall survival or progression free survival. As a result, patients often are misclassified too early as non-responders. As a consequence, successful treatment is not recognized or decisions towards a less effective second-line therapy are made. Dual Energy CT (DECT) is a new and robust CT method that allows to exactly quantify the intra-tumoral amount of intravenously injected iodinated contrast material PMID 21822784). Thus, the technique can be considered as a simple and reliable surrogate of tumor Perfusion (PMID 21822784, 21934517, 20498609, 18677487). Initial studies have demonstrated a high accuracy of DECT in the differentiation of benign and malignant tumors in the kidney or lung (PMID 20498609, 18677487, 18796658). Furthermore, it has been demonstrated that the amount of iodine in lung tumors correlates with tumor glucose metabolism (PMID 21822784). These findings confirm the results of previous studies that have demonstrated the relationship between tumor perfusion, tumor microvessel density and glucose metabolism (PMID 15304661). The hypothesis of the study is that DECT is the more accurate diagnostic tool to evaluate immediate therapeutic response in patients with GIST undergoing TKI inhibitor therapy (in most cases Glivec ®) than evaluating by RECIST, World Health Organization (WHO) and Choi criteria. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03404076
Study type Observational
Source Heidelberg University
Contact
Status Completed
Phase
Start date December 1, 2014
Completion date December 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT02574663 - TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT01991379 - MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT00623831 - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Phase 1
Completed NCT01294202 - A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST Phase 2
Completed NCT00785785 - A Study of Nilotinib Versus Imatinib in GIST Patients Phase 3
Recruiting NCT02443948 - Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) N/A
Recruiting NCT01034670 - Advanced Gastrointestinal Endoscopic Imaging N/A
Completed NCT00867113 - Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) Phase 2
Active, not recruiting NCT01391611 - Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) Phase 2
Terminated NCT02452424 - A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT03594422 - A Study of HQP1351 in Patients With GIST or Other Solid Tumors Phase 1
Recruiting NCT05453292 - Endoscopic Ultrasound Radiofrequency Ablation for GISTs N/A
Completed NCT00780494 - Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Phase 2
Recruiting NCT04557969 - Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Recruiting NCT04821895 - Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
Completed NCT01316263 - A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Recruiting NCT01048281 - Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma